Augmedix Statistics
Total Valuation
Augmedix has a market cap or net worth of $116.16 million. The enterprise value is $113.21 million.
| Market Cap | 116.16M |
| Enterprise Value | 113.21M |
Important Dates
The last earnings date was Monday, November 4, 2024, after market close.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Augmedix has 49.43 million shares outstanding. The number of shares has increased by 28.91% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 49.43M |
| Shares Change (YoY) | +28.91% |
| Shares Change (QoQ) | +0.62% |
| Owned by Insiders (%) | 1.61% |
| Owned by Institutions (%) | 39.83% |
| Float | 25.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.29 |
| Forward PS | 1.66 |
| PB Ratio | 11.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 2.41.
| Current Ratio | 1.66 |
| Quick Ratio | 1.56 |
| Debt / Equity | 2.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.39 |
Financial Efficiency
Return on equity (ROE) is -329.78% and return on invested capital (ROIC) is -46.95%.
| Return on Equity (ROE) | -329.78% |
| Return on Assets (ROA) | -30.61% |
| Return on Capital (ROIC) | -46.95% |
| Revenue Per Employee | $36,072 |
| Profits Per Employee | -$16,677 |
| Employee Count | 1,430 |
| Asset Turnover | 1.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Augmedix has paid $68,000 in taxes.
| Income Tax | 68,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.37% in the last 52 weeks. The beta is -0.19, so Augmedix's price volatility has been lower than the market average.
| Beta (5Y) | -0.19 |
| 52-Week Price Change | -54.37% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 2.97 |
| Relative Strength Index (RSI) | 74.05 |
| Average Volume (20 Days) | 62,299 |
Short Selling Information
The latest short interest is 1.07 million, so 2.16% of the outstanding shares have been sold short.
| Short Interest | 1.07M |
| Short Previous Month | 1.32M |
| Short % of Shares Out | 2.16% |
| Short % of Float | 4.25% |
| Short Ratio (days to cover) | 5.73 |
Income Statement
In the last 12 months, Augmedix had revenue of $51.58 million and -$23.85 million in losses. Loss per share was -$0.47.
| Revenue | 51.58M |
| Gross Profit | 24.87M |
| Operating Income | -23.88M |
| Pretax Income | -20.40M |
| Net Income | -23.85M |
| EBITDA | -22.47M |
| EBIT | -23.88M |
| Loss Per Share | -$0.47 |
Balance Sheet
The company has $28.22 million in cash and $25.28 million in debt, giving a net cash position of $2.95 million or $0.06 per share.
| Cash & Cash Equivalents | 28.22M |
| Total Debt | 25.28M |
| Net Cash | 2.95M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 10.47M |
| Book Value Per Share | 0.21 |
| Working Capital | 15.93M |
Cash Flow
In the last 12 months, operating cash flow was -$15.31 million and capital expenditures -$2.56 million, giving a free cash flow of -$17.87 million.
| Operating Cash Flow | -15.31M |
| Capital Expenditures | -2.56M |
| Free Cash Flow | -17.87M |
| FCF Per Share | -$0.36 |
Margins
Gross margin is 48.22%, with operating and profit margins of -46.29% and -46.23%.
| Gross Margin | 48.22% |
| Operating Margin | -46.29% |
| Pretax Margin | -46.10% |
| Profit Margin | -46.23% |
| EBITDA Margin | -43.55% |
| EBIT Margin | -46.29% |
| FCF Margin | -42.98% |
Dividends & Yields
Augmedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.91% |
| Shareholder Yield | -28.91% |
| Earnings Yield | -20.53% |
| FCF Yield | -15.39% |
Analyst Forecast
The average price target for Augmedix is $5.25, which is 123.40% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.25 |
| Price Target Difference | 123.40% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Augmedix has an Altman Z-Score of -1.74 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.74 |
| Piotroski F-Score | 3 |